Time to progression in relation to prognostic factors. (A) Median TTP depending on normal or elevated (≥ 297.5 nM [3.5 mg/L]) levels of β₂-microglobulin. The vertical axis represents the proportion of patients who are alive and progression-free. The horizontal axis represents time in weeks from first dose of study drug. The solid line represents patients with normal (less than 297.5 nM) β₂-microglobulin (n = 42) and the dotted line represents patients with elevated (≥ 297.5 nM) β₂-microglobulin (n = 17). (B) Median TTP in weeks depending on cytogenetic aberration 17p−. The vertical axis represents the proportion of patients who are alive and progression-free. The horizontal axis represents time in weeks from first dose of study drug. The solid line represents patients without 17p− (n = 32), and the dotted line represents patients with 17p− (n = 5).